In vivo evaluation of Cerenkov luminescence and SPECT imaging for nanoscale 177Lu-labeled metal-organic framework

IF 1.4 3区化学 Q4 CHEMISTRY, INORGANIC & NUCLEAR Radiochimica Acta Pub Date : 2024-09-12 DOI:10.1515/ract-2024-0306

Wenbing Ding, Jie Lyu, Yuying Yu, Fuyuan Tan, Ai Yang, Tu Lan, Jiali Liao, Yuanyou Yang, Ning Liu, Feize Li

{"title":"In vivo evaluation of Cerenkov luminescence and SPECT imaging for nanoscale 177Lu-labeled metal-organic framework","authors":"Wenbing Ding, Jie Lyu, Yuying Yu, Fuyuan Tan, Ai Yang, Tu Lan, Jiali Liao, Yuanyou Yang, Ning Liu, Feize Li","doi":"10.1515/ract-2024-0306","DOIUrl":null,"url":null,"abstract":"Multimodal imaging for precision medicine has received significant attention in recent years. In this work, we proposed to combine Cerenkov luminescence imaging (CLI) and SPECT-CT to systematically evaluate the real biodistribution of nanoscale metal-organic framework (MOF) in murine xenograft model. 177Lu was incorporated into nanoscale MOF-76(Eu)/FA in high radiochemical yield to construct a multimodal probe with physiological stability. Subsequently, the 177Lu-MOF-76(Eu)/FA shows adequate in vitro affinity and cytotoxicity to cancer cells. Furthermore, by comparing the SPECT imaging and CLI, we evaluated the feasibility of in vivo CLI application in preclinical studies of 177Lu-radiopharmaceuticals. The results demonstrate that CLI address some limitations of fluorescence imaging based on organic dye molecule and enable accurate tracking 177Lu radiolabeled compounds in major organs.","PeriodicalId":21167,"journal":{"name":"Radiochimica Acta","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiochimica Acta","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1515/ract-2024-0306","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}

引用次数: 0

Abstract

Multimodal imaging for precision medicine has received significant attention in recent years. In this work, we proposed to combine Cerenkov luminescence imaging (CLI) and SPECT-CT to systematically evaluate the real biodistribution of nanoscale metal-organic framework (MOF) in murine xenograft model. 177Lu was incorporated into nanoscale MOF-76(Eu)/FA in high radiochemical yield to construct a multimodal probe with physiological stability. Subsequently, the 177Lu-MOF-76(Eu)/FA shows adequate in vitro affinity and cytotoxicity to cancer cells. Furthermore, by comparing the SPECT imaging and CLI, we evaluated the feasibility of in vivo CLI application in preclinical studies of 177Lu-radiopharmaceuticals. The results demonstrate that CLI address some limitations of fluorescence imaging based on organic dye molecule and enable accurate tracking 177Lu radiolabeled compounds in major organs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纳米级 177Lu 标记金属有机框架的塞伦科夫发光和 SPECT 成像的体内评估

近年来，用于精准医疗的多模态成像技术备受关注。在这项工作中，我们提出将Cerenkov发光成像（CLI）和SPECT-CT结合起来，系统评估纳米级金属有机框架（MOF）在小鼠异种移植模型中的真实生物分布。将177Lu以高放射化学收率掺入纳米级MOF-76(Eu)/FA中，构建了一种具有生理稳定性的多模态探针。随后，177Lu-MOF-76(Eu)/FA 在体外显示出对癌细胞足够的亲和力和细胞毒性。此外，通过比较 SPECT 成像和 CLI，我们评估了体内 CLI 在 177Lu 放射药物临床前研究中应用的可行性。结果表明，CLI 解决了基于有机染料分子的荧光成像的一些局限性，并能在主要器官中准确追踪 177Lu 放射性标记化合物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊